$1.33
1.88%
Downside
Day's Volatility :4.68%
Upside
2.86%
53.38%
Downside
52 Weeks Volatility :73.16%
Upside
42.42%
Period | Atossa Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 6.4% | 0.0% |
6 Months | 20.91% | 0.0% |
1 Year | 78.88% | 0.0% |
3 Years | -63.66% | -22.3% |
Market Capitalization | 171.0M |
Book Value | $0.64 |
Earnings Per Share (EPS) | -0.21 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.42 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.68% |
Return On Equity TTM | -28.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -30.5M |
Diluted Eps TTM | -0.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.21 |
EPS Estimate Next Year | -0.27 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 307.52%
Sell
Neutral
Buy
Atossa Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Atossa Therapeutics Inc | 14.66% | 20.91% | 78.88% | -63.66% | -35.12% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Atossa Therapeutics Inc | NA | NA | 0.0 | -0.21 | -0.28 | -0.2 | NA | 0.64 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Atossa Therapeutics Inc | Buy | $171.0M | -35.12% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Atossa Therapeutics Inc
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 132.9%
BlackRock Inc
Vanguard Group Inc
Renaissance Technologies Corp
Geode Capital Management, LLC
Morgan Stanley - Brokerage Accounts
State Street Corporation
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
Organization | Atossa Therapeutics Inc |
Employees | 12 |
CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.33
-2.21%
Keyarch Acquisition Corp
$1.33
-2.21%
Connexa Sports Technologies Inc
$1.33
-2.21%
Us Value Etf
$1.33
-2.21%
First Wave Biopharma Inc
$1.33
-2.21%
Global X Msci Next Emerging
$1.33
-2.21%
Fat Projects Acquisition Corp
$1.33
-2.21%
Capital Link Global Fintech
$1.33
-2.21%
Applied Uv Inc
$1.33
-2.21%